Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial

scientific article

Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1371/JOURNAL.PNTD.0001289
P932PMC publication ID3196468
P698PubMed publication ID22028938
P5875ResearchGate publication ID51746862

P50authorJan HolmgrenQ5811529
Mohammad AliQ54268652
John ClemensQ58987399
Mahesh C PuriQ59820848
Anna Lena LopezQ73587266
Jacqueline L DeenQ87896207
Allan HardingQ110221149
Nirmal K. GangulyQ111307211
Dipika SurQ114445759
Suman KanungoQ114445760
Deok Ryun KimQ116774170
Binod SahQ116793834
Allison M PaisleyQ116793835
Banwarilal SarkarQ116793836
Rodney CarbisQ116793837
Raman RaoQ116793838
Stephen AttridgeQ116793839
P2093author name stringG Balakrish Nair
Sujit K Bhattacharya
Seung Hyun Han
Jin Kyung Park
Byomkesh Manna
Thu Van Nguyen
Swapan K Niyogi
P2860cites workDesign and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designQ24569560
Cholera vaccines for the developing world.Q37138956
Cholera outbreaks caused by an altered Vibrio cholerae O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to 2008.Q37191671
Field trial of a locally produced, killed, oral cholera vaccine in VietnamQ39439547
Cholera in Mozambique, variant of Vibrio choleraeQ42541007
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trialQ44235991
Field trial of oral cholera vaccines in BangladeshQ46726270
Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trialQ57926913
El Tor cholera with severe disease: a new threat to Asia and beyondQ57936162
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-upQ57936163
Cholera vaccines: WHO position paperQ83941810
P275copyright licenseCreative Commons Attribution 2.5 GenericQ18810333
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectcholera vaccineQ1812946
choleraQ12090
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)e1289
P577publication date2011-10-18
P1433published inPLoS Neglected Tropical DiseasesQ3359737
P1476titleEfficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial
P478volume5

Reverse relations

cites work (P2860)
Q533117435 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.
Q34484003A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mic
Q35645943An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India
Q24620207Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera
Q40545451Assessing different measures of population-level vaccine protection using a case-control study.
Q92264656Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine
Q47794110Causes of impaired oral vaccine efficacy in developing countries.
Q38370138Cholera - management and prevention.
Q37588131Cholera transmission dynamic models for public health practitioners
Q37225765Cholera vaccination in urban Haiti
Q41997569Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design
Q51732904Considerations around the introduction of a cholera vaccine in Bangladesh.
Q47602346Cost Evaluation of a Government-Conducted Oral Cholera Vaccination Campaign-Haiti, 2013.
Q34305452Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar
Q40217031Coverage and acceptability of cholera vaccine among high-risk population of urban Dhaka, Bangladesh
Q40145989Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh
Q26823170Critical analysis of compositions and protective efficacies of oral killed cholera vaccines
Q92264663Current and future cholera vaccines
Q47095750Delivery cost analysis of a reactive mass cholera vaccination campaign: a case study of Shanchol™ vaccine use in Lake Chilwa, Malawi
Q37643320Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
Q37225767Development of a cholera vaccination policy on the Island of Hispaniola, 2010-2013
Q36869585Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up
Q35261144Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis
Q38978824Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh
Q34403586Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide
Q40295575Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial
Q34994131Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea
Q57927158Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh
Q40088781Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.
Q64123267IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity
Q37360102Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan
Q38059916Immune responses and protection in children in developing countries induced by oral vaccines
Q33588522Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera
Q36044030Immune responses to cholera in children
Q34334260Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh
Q37340450Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length
Q47410855Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis
Q33552968Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti
Q64240401Impact of a Large-Scale Handwashing Intervention on Reported Respiratory Illness: Findings from a Cluster-Randomized Controlled Trial
Q47810215Impact of adding hand-washing and water disinfection promotion to oral cholera vaccination on diarrhoea-associated hospitalization in Dhaka, Bangladesh: evidence from a cluster randomized control trial
Q35963349Impact of oral cholera vaccines in cholera-endemic countries: A mathematical modeling study
Q30151668Improving immunization approaches to cholera
Q36654953Incidence of severe diarrhoea due to Vibrio cholerae in the catchment area of six surveillance hospitals in Bangladesh.
Q92339950Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh
Q41426133Insights from natural infection-derived immunity to cholera instruct vaccine efforts
Q45242442Introducing cholera vaccination in Asia, Africa and Haiti: a meeting report
Q35744920Is a Cholera Outbreak Preventable in Post-earthquake Nepal?
Q50054542Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate
Q34087755Killed oral cholera vaccines: history, development and implementation challenges
Q92296556Mapping cholera outbreaks and antibiotic resistant Vibrio cholerae in India: An assessment of existing data and a scoping review of the literature
Q33578033Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines
Q35940653Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh
Q35091566Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions
Q37225744Modeling the effect of water, sanitation, and hygiene and oral cholera vaccine implementation in Haiti
Q37953796New-generation vaccines against cholera
Q36881533O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh
Q38078460Old foes, new challenges: syphilis, cholera and TB.
Q36187863Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings
Q40440951Optimized oral cholera vaccine distribution strategies to minimize disease incidence: A mixed integer programming model and analysis of a Bangladesh scenario
Q64130108Organization and implementation of an oral cholera vaccination campaign in an endemic urban setting in Dhaka, Bangladesh
Q51150718PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Q40189342Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh
Q34456242Post-licensure deployment of oral cholera vaccines: a systematic review
Q92574357Preventing cholera in India: Synthesizing evidences through a systematic review for policy discussion on the use of oral cholera vaccine
Q51784737Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects.
Q39448785Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis
Q21090119Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks
Q36153627Retrospective Analysis of Serotype Switching of Vibrio cholerae O1 in a Cholera Endemic Region Shows It Is a Non-random Process
Q64951541Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Q48344793Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Q64054143Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial
Q34359766Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy
Q37992392Safety reporting in developing country vaccine clinical trials-a systematic review
Q36593379Socio-cultural determinants of anticipated acceptance of an oral cholera vaccine in Western Kenya
Q35892956Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach
Q57481187The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships
Q35867213Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice
Q37130173Trials and tribulations of conducting interventional studies in urban slums of a developing country: Experiences from Kolkata, India
Q34474623Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau
Q28080866Vaccines against enteric infections for the developing world
Q26995690Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus
Q27004488Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae
Q33572955Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India

Search more.